Lung Cancer
Conditions
Interventions
case series:None
Sponsors
Cancer Hospirtal Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The clinicopathological diagnosis was stage ?C and ? NSCLC; 2. NSCLC patients whose PS score was 0-2 and intended to receive first-line, third-generation EGFR-TKIs targeted therapy; 3. Adequate blood (required) or tumor tissue samples (recommended) can be provided before, after and during disease progression; 4. Complete clinical and pathological data, such as age, gender, smoking history, primary tumor site, differentiation degree, metastatic site, etc., and complete imaging and serological review as required; 5. Regular follow-up can be accepted, and relevant information such as treatment process, efficacy and prognosis can be provided.
Exclusion criteria
Exclusion criteria: 1. Currently participating in interventional clinical studies or receiving other drugs or using research instruments after being diagnosed with advanced lung cancer; 2. In the judgment of the investigator, the patient may have other factors that may interfere with the study results and lead to the termination of the study, such as other serious diseases or serious abnormalities in laboratory tests, or other family or social factors that may affect the safety of the subjects or the collection of test data and samples, or other potential risks that the investigator deems unsuitable for participating in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Overall Survival;Blood TMB Expression; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;ctDNA Dynamic Changes; | — |
Countries
China
Contacts
Public ContactDuan Jianchun
Cancer Hospirtal Chinese Academy of Medical Sciences
Outcome results
None listed